Advances of treatment for nature killer/T-cell lymphoma.
10.7534/j.issn.1009-2137.2014.05.051
- Author:
Hong WANG
1
;
Xue-Yi PAN
2
Author Information
1. Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical College, Guangzhou 510080, Guangdong Province, China.
2. Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical College, Guangzhou 510080, Guangdong Province, China. E-mail: xypan88@163.com.
- Publication Type:Journal Article
- MeSH:
Asparaginase;
China;
Herpesvirus 4, Human;
Humans;
Killer Cells, Natural;
Lymphoma, T-Cell;
diagnosis;
therapy;
Prognosis
- From:
Journal of Experimental Hematology
2014;22(5):1453-1458
- CountryChina
- Language:Chinese
-
Abstract:
NK/T cell lymphoma (NKTCL) is a rare type of non-Hodgkin's lymphoma, occurs more frequently in Asia and Latin America. In China, NKTCL accounts for 30.1% in T-NHL and is highly related with EBV (Epstein-Barr virus) infection. This disease is highly aggressive, not sensitive to chemotherapy, with poor prognosis. The mean survival time is about 12-38 months. It is important to accurately assess the patient's stage of progression for an optimal treatment. For stageI-II, the combined chemotherapy and radiotherapy have better therapeutic effects. As for stage III-IV NKTCL, especially for non-nasal and aggressive subtypes, the chemotherapy is the main treatment method. For advanced disease, combining therapy is the most commonly selected approach, such as high-intensity chemotherapy combined with radiation and a regimen containing L-asparaginase (L-Asp) will benefit to patients. Recently, some studies have demonstrated that promising outcomes have been found in selected cases by high-dose chemotherapy supplemented with auto-or allo-HSCT. Targeting therapy is also an optimal choice. This review mainly focuses on the advance of treatment for NKTCL.
